We are live on
!
Find out more
FP
Foundry Partners Portfolio holdings
AUM
$1.89B
1-Year Est. Return
9.84%
This Fund
S&P 500
This Quarter
Est. Return
+1.27%
1 Year Est. Return
+9.84%
3 Year Est. Return
+44.42%
5 Year Est. Return
+233.04%
10 Year Est. Return
+297.72%
AUM
$2.42B
AUM Growth
-$119M
(-4.7%)
Cap. Flow
-$116M
Cap. Flow
% of AUM
-4.8%
Top 10 Holdings %
Top 10 Hldgs %
11.89%
Holding
424
New
35
Increased
125
Reduced
216
Closed
37
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Altria Group
MO
|
+$22.3M |
| 2 |
AES
AES
|
+$14M |
| 3 |
SNV
Synovus
SNV
|
+$13.3M |
| 4 |
Delta Air Lines
DAL
|
+$12.8M |
| 5 |
Albemarle
ALB
|
+$11.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan plc
AGN
|
+$21.4M |
| 2 |
Cisco
CSCO
|
+$18.9M |
| 3 |
Johnson & Johnson
JNJ
|
+$16.4M |
| 4 |
HP
HPQ
|
+$13.9M |
| 5 |
GSK
GSK
|
+$13.4M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Financials | 24.35% |
| 2 | Industrials | 15.2% |
| 3 | Technology | 9.4% |
| 4 | Healthcare | 8.25% |
| 5 | Consumer Discretionary | 8.17% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
251
Anika Therapeutics
ANIK
$195M
| $2.17M | 0.09% |
39,615
-15,300
| -28% | -$786K |
|
252
Ingevity
NGVT
$2.56B
| $2.14M | 0.09% |
25,210
-49
| -0.2% | -$4.37K |
|
253
Allot
ALLT
$365M
| $2.13M | 0.09% |
264,715
-15,750
| -6% | -$120K |
|
254
Covenant Logistics
CVLG
$1.21B
| $2.13M | 0.09% |
+259,550
| New | +$2M |
|
|
CTLT
255
DELISTED
CATALENT, INC.
CTLT
| $2.13M | 0.09% |
44,594
-96
| -0.2% | -$5.16K |
|
256
Coherent
COHR
$61.3B
| $2.12M | 0.09% |
60,186
+8,745
| +17% | +$333K |
|
257
Wingstop
WING
$3.67B
| $2.09M | 0.09% |
23,942
-13,746
| -36% | -$1.31M |
|
258
Wendy's
WEN
$1.37B
| $2.05M | 0.08% |
102,785
-218
| -0.2% | -$4.35K |
|
259
Northrim BanCorp
NRIM
$604M
| $2.02M | 0.08% |
203,600
-11,900
| -6% | -$111K |
|
|
AZPN
260
DELISTED
ASPEN TECHNOLOGY INC
AZPN
| $1.99M | 0.08% |
16,155
-3,843
| -19% | -$473K |
|
261
SPS Commerce
SPSC
$2.17B
| $1.98M | 0.08% |
42,102
+12,614
| +43% | +$640K |
|
262
Monolithic Power Systems
MPWR
$68.6B
| $1.96M | 0.08% |
12,585
-203
| -2% | -$30.4K |
|
|
QTS
263
DELISTED
QTS REALTY TRUST, INC.
QTS
| $1.82M | 0.08% |
+35,506
| New | +$1.69M |
|
264
Ramaco Resources Class A
METC
$731M
| $1.8M | 0.07% |
499,247
+12,978
| +3% | +$55.9K |
|
265
Funko
FNKO
$319M
| $1.8M | 0.07% |
87,503
+15,796
| +22% | +$365K |
|
|
BELFB
266
Bel Fuse Inc Class B
BELFB
$4.07B
| $1.79M | 0.07% |
119,190
-5,300
| -4% | -$73.4K |
|
|
EVOP
267
DELISTED
EVO Payments, Inc. Class A Common Stock
EVOP
| $1.77M | 0.07% |
62,951
+17,068
| +37% | +$501K |
|
268
Dick's Sporting Goods
DKS
$18.3B
| $1.77M | 0.07% |
43,304
-15,460
| -26% | -$557K |
|
|
KNL
269
DELISTED
Knoll, Inc.
KNL
| $1.75M | 0.07% |
68,863
-146
| -0.2% | -$3.46K |
|
|
HIL
270
DELISTED
Hill International, Inc. Common Stock
HIL
| $1.74M | 0.07% |
580,765
-34,800
| -6% | -$101K |
|
271
Addus HomeCare
ADUS
$2.09B
| $1.73M | 0.07% |
+21,831
| New | +$1.77M |
|
272
Trex
TREX
$4.4B
| $1.73M | 0.07% |
+38,012
| New | +$1.53M |
|
273
Tandem Diabetes Care
TNDM
$1.16B
| $1.7M | 0.07% |
28,769
-62
| -0.2% | -$3.96K |
|
274
HUB Group
HUBG
$3.01B
| $1.69M | 0.07% |
72,692
-170
| -0.2% | -$3.61K |
|
275
Etsy
ETSY
$7.68B
| $1.69M | 0.07% |
29,857
-63
| -0.2% | -$3.71K |
|
Similar funds
ST
UH
PAME
TW
AP
MBA
SSB
CC
Foundry Partners's Q3 2019 Portfolio in Review
As of Q3 2019, Foundry Partners held 424 positions worth $2.42B, down 4.7% from $2.54B the previous quarter. Its ten largest holdings account for 12% of the portfolio.
Foundry Partners withdrew a net $116M in Q3 2019, closing 37 positions and reducing 216 holdings. Its most notable exit was Allergan plc, an estimated $21.4M position sold in full.
By sector, the portfolio is most concentrated in Financials at 24% of assets, down from 25% a quarter earlier, followed by Industrials and Technology.
Against the trend, Foundry Partners opened a new position in Altria Group worth $19.8M.
- Foundry Partners's largest Q3 2019 buy was Altria Group: 484,800 shares worth $19.8M.
- Foundry Partners added most to Gilead Sciences in Q3 2019, an estimated $11.6M increase.
- Foundry Partners's biggest Q3 2019 reduction was Cisco, cutting an estimated $18.9M.
- Foundry Partners fully exited Allergan plc in Q3 2019, selling an estimated $21.4M.
- Foundry Partners's ten largest holdings make up 12% of its $2.42B portfolio in Q3 2019.
- Foundry Partners opened 35 new positions and closed 37 in Q3 2019.
- Foundry Partners's portfolio value fell 4.7% quarter-over-quarter to $2.42B.
Based on Foundry Partners's 13F filing for Q3 2019, filed 23 Oct 2019.